Growing community of inventors

Ingelheim am Rhein, Germany

Janine Lamar

Average Co-Inventor Count = 3.78

ph-index = 2

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 6

Janine LamarMichael Aven (7 patents)Janine LamarBalazs Albrecht (7 patents)Janine LamarIngo Lang (4 patents)Janine LamarMatthias Hausmann (1 patent)Janine LamarBenjamin Franzmann (1 patent)Janine LamarSudha Visvanathan (1 patent)Janine LamarSteven John Padula (1 patent)Janine LamarJay Fine (1 patent)Janine LamarMeera Ramanujam (1 patent)Janine LamarJanine Lamar (8 patents)Michael AvenMichael Aven (25 patents)Balazs AlbrechtBalazs Albrecht (7 patents)Ingo LangIngo Lang (11 patents)Matthias HausmannMatthias Hausmann (20 patents)Benjamin FranzmannBenjamin Franzmann (6 patents)Sudha VisvanathanSudha Visvanathan (2 patents)Steven John PadulaSteven John Padula (1 patent)Jay FineJay Fine (1 patent)Meera RamanujamMeera Ramanujam (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Boehringer Ingelheim Vetmedica Gmbh (5 from 306 patents)

2. Other (2 from 832,680 patents)

3. Boehringer Ingelheim International Gmbh (1 from 1,535 patents)


8 patents:

1. 12098207 - Anti-IL-36R antibodies for the treatment of pyoderma gangrenosum

2. 10925964 - Pharmaceutical formulation comprising ciclesonide

3. 10682345 - Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

4. 10441597 - Ciclesonide for the treatment of airway disease in horses

5. 10342789 - Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

6. 10258634 - Ciclesonide for the treatment of airway disease in horses

7. 9918995 - Ciclesonide for the treatment of airway disease in horses

8. 9474747 - Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/7/2025
Loading…